Oxford Global w/ Dr Ana Leite

Join our Director of Bioinformatics, Dr Ana Liete, for a talk on data driven approaches for precision medicine.

The Oxford Global Pharma Data congress showcases success in FAIR data implementation, data analytics, AI/ML technologies, RWE generation, scaling up data storage and infrastructure, leveraging multi omic datasets and data management strategies to help elevate research.

Ana will give a talk on data driven approaches to precision medicine, including;

  • How different approaches can be used to analyse patient clinical, genetics and genomics data
  • Implementing AI-augmented workflows to uncover insights from patient level data

Event website →

Ana Leite

Director of Bioinformatics

Ana is responsible for leading the Product & Tech strategy for Precision Medicine at BenevolentAI, taking a patient centric approach to understand disease endotypes, mechanisms and targets. At BenevolentAI Ana also delivered a strategy for an end to end flow of Omics data, ensuring integration with the Knowledge Graph and long-term value of data assets according to FAIR principles. Prior to joining BenevolentAI Ana worked at GSK where she executed digital strategy and led bioinformatics research to drive target discovery strategies. Ana received her PhD in Computational and Systems Biology at MIT and completed her postdoctoral training at UCL Cancer Institute.

More Posts

You Might Also Like

Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022